Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
← catalyst calendarNCT02781883 · readout ≤ 499 d
Sponsored by Bio-Path Holdings, Inc. (industry) · BPTH — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
108estimated
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | May 2016 | not stated | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2016-05-25 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Myeloid Leukemia (AML)
Interventions
- Drug: BP1001 in combination with Ventoclax plus decitabine — also filed as Liposomal Grb-2, L-Grb-2
- Drug: BP1001 plus decitabine — also filed as Liposomal Grb-2, L-Grb-2
Primary outcomes
what the primary-completion date above is the date OFAssessment of efficacy in untreated AML subjects by bone marrow aspirate or biopsy
measured 180 days
Assessment of efficacy in refractory/relapsed AML subjects by bone marrow aspirate or biopsy
measured 180 days
Permalink · BPTH's whole pipeline · Catalyst calendar · Every registered study · What changed